RA
OTLK icon

Rosalind Advisors’s Outlook Therapeutics OTLK Stock Holding History

Rosalind Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-450,000
Closed -$2.4M – 48
2024
Q3 		$2.4M Hold
450,000
– – 1.54% 18
2024
Q2 		$3.32M Buy
450,000
+138,225
+44% +$1.11M 2.56% 19
2024
Q1 		$3.72M Buy
+311,775
New +$2.52M 3.48% 14

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rosalind Advisors's OTLK Position: Q4 2024 in Review

Rosalind Advisors sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 450,000 shares — an estimated $2.4M sold.

Rosalind Advisors first reported a position in OTLK in Q1 2024 and held it in 3 quarters. The position peaked at $3.72M in Q1 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Rosalind Advisors reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rosalind Advisors sold 450,000 Outlook Therapeutics shares in Q4 2024, an estimated $2.4M.
  • Rosalind Advisors first reported a position in Outlook Therapeutics in Q1 2024 and held it in 3 quarters.
  • Rosalind Advisors's Outlook Therapeutics position peaked at $3.72M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.